Indivior Pharmaceuticals Reports 14% Revenue Growth in Q2 2026, Announces Merger with Supernus

Indivior Pharmaceuticals, Inc. reported a significant increase in financial performance for the second quarter of 2026, with net revenue reaching $343 million, a 14% increase from $302 million in the same period of 2025. For the first half of 2026, the company generated $660 million in revenue, up 16% from $568 million year-over-year. The growth was primarily driven by strong sales of its flagship product, SUBLOCADE, which accounted for 74% of total revenue, reflecting a 22% increase in the second quarter and a 27% increase in the first half compared to the previous year. The company's gross profit also improved, rising to $294 million in Q2 2026 from $250 million in Q2 2025, resulting in a gross margin of 85%.

Operating income for the second quarter surged to $160 million, compared to $72 million in the same quarter of 2025, while net income increased to $122 million from $18 million. This resulted in earnings per share of $1.02 for the second quarter, a substantial rise from $0.15 in the prior year. The company attributed these improvements to increased dispense unit volume and favorable pricing for SUBLOCADE, alongside a reduction in operating expenses, which fell by 25% in Q2 2026 compared to the same period in 2025.

In terms of strategic developments, Indivior announced a merger agreement with Supernus Pharmaceuticals on August 1, 2026. This all-stock merger is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals. The merger will result in Indivior being renamed Supernus Pharmaceuticals, Inc. and aims to enhance the combined company's market position. Additionally, the company has initiated a $400 million share repurchase program, of which $300 million has already been utilized to repurchase shares.

Operationally, Indivior's customer engagement metrics showed positive trends, with SUBLOCADE's dispense unit volume growing by 18% and 19% in the second quarter and first half of 2026, respectively. However, the company experienced a decline in revenue from its international markets, with net revenue from the Rest of the World decreasing by 7% in Q2 2026 compared to the previous year, attributed to the exit from certain non-U.S. markets. As of June 30, 2026, Indivior had 118 million shares of common stock outstanding and reported cash and cash equivalents of $222 million.

Looking ahead, Indivior's management expressed optimism about the future, emphasizing the anticipated benefits of the merger with Supernus and the ongoing commitment to its core business in opioid use disorder treatments. However, they acknowledged potential risks associated with the merger, including the need for stockholder approvals and the possibility of delays in completion. The company remains focused on maintaining its market position and ensuring liquidity to meet its operational needs in the coming year.